Bolt Biotherapeutics to Participate in Upcoming March Conferences

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced management will participate in two March 2026 investor events: a company presentation at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:50 a.m. EST and one‑on‑one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026.

News Market Reaction – BOLT

+3.67%

1 alert

+3.67% News Effect

+$358K Valuation Impact

$10M Market Cap

0.1x Rel. Volume

On the day this news was published, BOLT gained 3.67%, reflecting a moderate positive market reaction. This price movement added approximately $358K to the company's valuation, bringing the market cap to $10M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Number of conferences: 2 conferences TD Cowen presentation date: March 2, 2026 TD Cowen presentation time: 9:50 a.m. EST +1 more

4 metrics

Number of conferences 2 conferences March investor/healthcare conferences

TD Cowen presentation date March 2, 2026 TD Cowen 46th Annual Health Care Conference

TD Cowen presentation time 9:50 a.m. EST Company presentation slot

Leerink 1x1 meeting date March 11, 2026 Leerink Partners Global Healthcare Conference

Market Reality Check

Price: $4.90 Vol: Volume 14,474 is below th...

low vol

$4.90 Last Close

Volume Volume 14,474 is below the 20-day average of 34,307, indicating subdued pre-news activity. low

Technical Shares at $4.91 are trading below the 200-day moving average of $5.67 and about 52.3% under the 52-week high.

Peers on Argus

Momentum scanner shows mixed peer action, with ERNA up about 1.37% and RNAZ down...

1 Up 1 Down

Momentum scanner shows mixed peer action, with ERNA up about 1.37% and RNAZ down about 5.07%, suggesting no clear sector-wide driver around this conference update.

Historical Context

2 past events · Latest: Nov 12 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Nov 12	Q3 2025 earnings	Positive	-2.5%	Reported Q3 results with higher collaboration revenue and lower operating loss.
Oct 01	Pipeline and cash update	Negative	+6.4%	Updated BDC-4182 trial timeline and announced 50% workforce reduction to extend runway.

Pattern Detected

Recent news events show price reactions often diverging from the apparent tone of the announcements.

Recent Company History

Recent Bolt news has centered on financial updates and pipeline progress. On Oct 1, 2025, the company announced a Phase 1 protocol change for BDC-4182 and a 50% workforce reduction, yet shares rose about 6.39%. On Nov 12, 2025, Bolt reported Q3 results with improved operating loss and cash of $38.8M, but the stock slipped roughly 2.49%. Today’s conference participation fits the ongoing communication cadence.

Market Pulse Summary

This announcement highlights upcoming March conference appearances, which can give Bolt an opportuni...

Analysis

This announcement highlights upcoming March conference appearances, which can give Bolt an opportunity to reinforce its clinical story and strategy with investors. In recent months, the company outlined pipeline progress, a 50% workforce reduction, and Q3 cash of $38.8M, extending runway into 2027. Investors may watch these meetings for incremental commentary on BDC‑4182 timelines, collaboration updates, and any refinements to spending plans.

Key Terms

clinical-stage, biopharmaceutical, immunotherapies

3 terms

clinical-stage medical

"a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

biopharmaceutical medical

"a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

immunotherapies medical

"company developing novel immunotherapies for the treatment of cancer, today announced"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:

• TD Cowen 46th Annual Health Care Conference
  Company presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST)
  
• Leerink Partners Global Healthcare Conference
  Participating in 1x1 meetings on Wednesday, March 11, 2026

About Bolt Biotherapeutics, Inc.
The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1 dose escalation trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company’s Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform technology and its expertise in myeloid biology. The Company is seeking to partner BDC-3042, a Dectin-2 agonist that recently completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1.
For more information, please visit https://www.boltbio.com/.

Investor Relations and Media Contact:
Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com

FAQ

When will Bolt (BOLT) present at the TD Cowen 46th Annual Health Care Conference?

Bolt will present at TD Cowen on Monday, March 2, 2026 at 9:50 a.m. EST. According to the company, the presentation slot is scheduled at 9:50 a.m. EST and is intended to communicate updates on its clinical‑stage immunotherapy programs and corporate developments.

Does the Bolt (BOLT) announcement include a public webcast or presentation link for March 2, 2026?

There is no webcast or public presentation link specified in the announcement for Bolt's March 2 TD Cowen session. According to the company, only the date, time, and participation were disclosed; investors should monitor company channels for any later webcast details.

What will Bolt management discuss at the March 2026 conferences (BOLT)?

Management will present at TD Cowen on March 2 and hold 1x1 meetings at Leerink on March 11, 2026. According to the company, these events provide updates on its clinical‑stage immunotherapy development and offer opportunities for direct investor engagement.

How can investors request a one‑on‑one meeting with Bolt (BOLT) at the Leerink conference?

Bolt is participating in one‑on‑one investor meetings at the Leerink Partners Global Healthcare Conference on March 11, 2026. According to the company, interested investors should contact conference organizers or the company's investor relations team to inquire about scheduling 1x1 meetings.

Will Bolt's (BOLT) conference participation on March 2 and March 11, 2026 include new financial guidance or material disclosures?

The announcement is a conference participation notice and does not include financial guidance or material transactions. According to the company, these dates are for presentation and meetings only; investors should await formal clinical or financial disclosures for potential stock‑moving information.